Echosens proudly announces the publication of the “FibroScan-AST (FAST) Score in The Lancet Gastroenterology & Hepatology.
Read More
Echosens proudly announces the publication of the “FibroScan-AST (FAST) Score in The Lancet Gastroenterology & Hepatology.
Echosens aligns with the Fatty Liver Foundation to accelerate screening for undiagnosed NAFLD-NASH patients.
Echosens calls for increased vigilance by healthcare providers to monitor liver health at the point of care, address obesity, diabetes and halt progression of NAFLD.
Echosens will provide a live demonstration of a FibroScan examination, in partnership with Fidelis, at the Department of Veterans Affairs’ (VA) National Veterans Small Business Engagement
FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.
Echosens joins the American Liver Foundation in observance of Liver Cancer Awareness Month, urging increased awareness of non-alcoholic fatty liver disease (NAFLD) and its more severe form called non-alcoholic steatohepatitis (NASH
Addressing the risk for cirrhosis, liver failure and liver cancer among America’s veterans
Featuring in-depth discussions with physicians and administrators at some of the nation’s leading Federally Qualified Health Centers.
Global Healthcare Business and Technology Expert Leads Company Growth in Chronic Liver Disease Assessment
